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THE secretory leucocyte proteinase inhibitor (SLPI) is
a  low molecular weight, tissue-specific  inhibitor  of,
for  example,  elastase  and  cathepsin  G,  which  also
have antimicrobial capacity. SLPI has been localised
to the respiratory, gastrointestinal and genital tracts,
but so far not to the kidney. The presence of SLPI in
renal tubuli  cells was demonstrated using immuno-
histochemistry and, by means of in situ hybridisation
on  human renal biopsies,  we were  able  to  demon-
strate SLPI production. In various inflammatory con-
ditions  in  the  kidneys,  the  protease-antiprotease
balance is disturbed. For this reason, as well as the
possible role in the defence against ascending urinary
tract infections, it is interesting to establish a source
of SLPI in renal tubuli cells.
Key  words:  Glomerulonephritis,  Kidney,  Protease  inhib-
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Introduction
Secretory leukocyte proteinase inhibitor  (SLPI) is  a
107 amino acid non-glycosylated single chain protein,
stabilised  by  intrachain  disulphide  bonds. The  esti-
mated molecular weight of the acid-stable protein is
12kDa. The C-terminal is responsible for the inhibi-
tory  activity  against  elastase,  cathepsin  G,  chymo-
trypsin and trypsin, whereas the N-terminal has been
reported to possess antimicrobial capacity.1,2 SLPI is
also known to inhibit HIV type 1 by blocking DNA
synthesis.3 The Kazal-type inhibitor forms complexes
with the proteases and has a half-life of 10min in the
circulation. The complexes formed locally dissociate
in  plasma and the proteases are taken over by  the
plasma protease inhibitors (alpha-1-antitrypsin, alpha-
2-macroglobulin  and  antichymotrypsin).1 Further-
more, SLPI has been shown to inhibit elastin-bound
elastase, which may be of importance for the preser-
vation  of  elastic  lung  tissue.4 The  inhibitor  is  also
capable of upregulation of macrophage production of
the  anti-inflammatory  cytokines  interleukin-10  and
transforming growth factor-b.5The SLPI gene contains
binding sites for transcription factors induced by, for
example, tumour necrosis factor-a, and an upregula-
tion of SLPI is seen in several inflammatory disorders.6
The physiological functions of SLPI are probably to
buffer the extracellular protease-mediated effects of
inflammatory leukocytes, as well as participating in
the antimicrobial defence. SLPI has until now mainly
been  found  in  mucosa  (e.g.  in  the  respiratory,
gastrointestinal  and  genital  tracts).  Less  is  known
about SLPI in solid organs, although production was
recently  established  in  human  pancreatic  b cells,
indicating an autocrine/paracrine function.7
The aim of the study presented here was to clarify
whether there is a local renal production of SLPI. A
possible local production would be of great interest,
considering  the  multitude  of  inflammatory  condi-
tions, including different kinds of glomerulonephritis
and nephritis, involving the kidneys. Anti-neutrophilic
cytoplasmic  antibodies  (ANCA)  are  autoantibodies
directed against constituents of  polymorphonuclear
neutrophils and monocytes, associated with systemic
vasculitis and glomerulonephritis. One of the ANCA
antigens, proteinase 3, has the capacity to attack and
degrade components of the extracellular vessel wall
matrix and the glomerular basement membrane. In
blood,  it  is  immediately  bound,  mainly  by  alpha-
1-antitrypsin. Patients with ANCA-associated vasculitis
have an over-representation of the PiZ gene of alpha-
1-antitrypsin and thus a lack of the inhibitor.8 SLPI has
no direct inhibitory capacity against proteinase 3; it
can, on the contrary, be degraded proteolytically by
it.1 Although SLPI has no direct inhibitory capacity
against  proteinase  3,  the  progressive  binding  of
elastase to SLPI instead of alpha-1-antitrypsin has been
shown to be paralleled by an increasing binding of
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SLPI may indirectly aid in the binding and inhibition
of  proteinase  3.  SLPI  is  also  an  inhibitor  of  the
production of matrix metalloproteinases (MMP) and,
knowing that MMP expression and activity are greatly
elevated in inflammatory disorders of the kidney, a
possible  renal  production  would  be  very  inter-
esting.10,11 A  possible  role  in  the  defence  against
ascending urinary tract infections also draws attention
to the point of issue.
Subjects and methods
Patient material
Macroscopically and microscopically normal kidney
preparations were selected from three different speci-
mens obtained at  the  time  of  nephrectomy due to
renal cancer. The Helsinki declaration regarding the
use of human tissues was strictly observed.
Materials and chemicals
Normal rabbit serum was purchased from Dakopat AB
(Copenhagen, Denmark). Swedish landrace goats were
immunised with recombinant human SLPI, to produce
anti-SLPI antiserum. Biotinylated rabbit anti-goat IgG
and avidin-biotinylated horseradish peroxidase com-
plexes  were  from Vector  Laboratories (Burlingame,
CA, USA). The AEC substrate-chromogen system and
Faramount  aqueous  mounting  medium  were  from
Dako Corporation (Carpinteria, CA, USA). An oligonu-
cleotide probe cocktail for SLPI was from R&D systems
(Abingdon,  UK).  Blocking  reagent  and  anti-digox-
igenin (DIG)-AP conjugate (Fab fragments) were from
Boehringer Mannheim (Mannheim, Germany). Visual-
ising  substrates  (bromochloroindolylphosphate
(BCIP) and nitroblue tetrazolium (NBT)) were from
Bio-Rad Laboratories (Hercules, CA, USA).
Immunohistochemistry
The frozen renal tissue specimens were fixed in 4%
buffered formaldehyde, dehydrated and embedded in
paraffin wax for sectioning on sialinised slides. After
rehydration,  the  sections  were  exposed  to  pepsin
(4mg/ml  in  0.01M  HCl)  for  20min  at  37°C. The
sections were  then  washed between  every  step  in
Tris-buffered  saline  (TBS),  3  ´ 5min.  Endogenous
peroxidase activity was removed by incubation of the
specimens in 0.3% H2O2 in methanol for 30min at
room temperature. Normal rabbit serum (3% in TBS)
was applied to block non-specific staining. The next
step, after draining, was to incubate the specimens
with  primary  antibody  (goat  anti-SLPI,  1/1000,
30min).  For  detection, we used  biotinylated rabbit
anti-goat IgG  (5mg/ml),  followed  by  application  of
avidin-biotinylated horseradish peroxidase complexes
for 30min. Visualisation was accomplished by  addi-
tion of AEC (0.75mg/ml of 3-amino-9-ethylcarbazole
in  2.5% N,N-dimethylformamide and 50 mM  acetate
buffer) that was left to incubate for 15min. The slides
were washed and counterstained before mounting. All
the  incubations  were  carried  out  at  room
temperature.
Adsorbed anti-SLPI antiserum, obtained by affinity
chromatography  on  a  SLPI-conjugated  Sepharose
4B-column,  was  used  as  a  negative  control  and
applied instead of the primary antibody.
In situ hybridisation
A  cocktail  of  three  30-base  long  oligonucleotide
probes  (59-TCTTAGGAGGACAGACTC  CAGCTTT-
GAAGG-39,  59-ATTTCCCACACATGCCCATG  CAA-
CACTTCA-39,  59-AAC  ATCTCTTCTTCCCTGGA-
CACTGCCAGT-39), based on the antisense sequence
of SLPI and labelled with DIG at the 59 end, was used
for  the  in  situ hybridisation.  Diethylpyrocarbonate
was added to the millipore water and all solutions to
block RNAse activity. All solutions were autoclaved or
sterilised by filtration.
Renal tissue was taken immediately after surgery,
put  into  liquid  nitrogen and stored at  –70°C. After
sectioning  on  sialinised slides,  the specimens  were
left to dry in air. After fixation (4% paraformaldehyde
in 1 ´ phosphate-buffered saline (PBS), 2h, 4°C), the
slides  were  incubated  in  a  sucrose  solution  (30%
sucrose in 1 ´ PBS, overnight, 4°C). Washing in 1 ´
PBS for  2 ´ 5min  was followed by  treatment with
0.1M glycine, 2 ´ 5min. After further washing in 1 ´
PBS for 2 ´ 5min, the sections were placed in 0.3%
Triton X-100 in 1 ´ PBS for 15min. Washing in 1 ´ PBS,
2 ´ 5min, was followed by incubation with protei-
nase K (1mg/ml) in TE buffer for 30min at 37°C. After
post-fixation (4% paraformaldehyde in 1 ´ PBS, 5min,
4°C) and PBS washing, 2 ´ 5min, the sections were
acetylated  in  a  0.1M  triethanolamine  (TEA)  buffer
(pH  8)  with  0.25%  acetic  anhydride.  TEA  blocks
endogenous  activity  of  alkaline  phosphatase,  and
acetanhydride reduces probe stickiness.
Incubation  with  40ml  pre-hybridisation  buffer  at
37°C for 2h preceded the pre-hybridisation, which
was  performed  in  a  moist  chamber.  To  prevent
evaporation, the specimens were covered with paraf-
ilm. The  probe  cocktail  (10ng  in  40ml  of  hybrid-
isation  buffer)  was  added  and  left  to  hybridise
overnight  at  37°C,  which  is  23°C  below  Tm. This
temperature  was  chosen because  of  short  oligonu-
cleotides. The slides were then washed in 2 ´ SSC (2
´ 5min),  1 ´ SSC (2 ´ 15min)  and 0.25  SSC (2 ´
15min) in a shaking water bath at 37°C. The slides
were  then  immersed  in  buffer  I (100 mM Tris-HCl,
150 mM NaCl; pH 7.5)  for 2 ´ 10min, followed by
treatment  with  buffer  II  (buffer  I  +  0.5%  blocking
reagent), to block non-specific anti-DIG binding. The
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anti-DIG-AP conjugate (1/500 in buffer I, 0.1% Triton
X-100  and  1%  normal  sheep  serum)  was  applied.
Repetition of buffer I washing was carried out for 2 ´
10min.  The  slides  were  then  placed  in  buffer  III
(100 mM Tris-HCl, 100 mM NaCl, 50 mM MgCl2; pH
9.5) for 10min. Visualisation was achieved by incuba-
tion in 10ml buffer III, 45ml of NBT, 35ml of BCIP and
1 mM Levamisole (240mg/ml) for 2–4h. The sections
were  then  mounted  using  an  aqueous  mounting
solution. Control sections were incubated with the
matched  sense-probes  or  with  hybridisation  buffer
without probes.
Results
Immunohistochemical staining  for  SLPI was carried
out on healthy kidney biopsies with positive staining
results (Fig. 1) in the distal tubuli. In negative control
sections incubated with adsorbed anti-SLPI antiserum,
the  positive  staining  was  completely  abolished. As
seen  in  Fig.  2,  a  positive  hybridisation  signal  was
obtained  in  the  tubuli  cells  of  the  healthy  kidney
biopsies.  In  negative  controls,  incubated  without
probes  and  with  sense  probes,  respectively,  no
positive signal was seen.
Discussion
SLPI is considered to be a major protease inhibitor in
the respiratory as well as in the gastrointestinal and
genital  tracts. A  potential  role  in  the  urinary  tract
could  therefore  be  anticipated.  In  this  study,  both
immunohistochemistry  and  in  situ hybridisation
(ISH) showed clearly positive results, with no back-
ground staining and adequate controls. The positive
staining of SLPI in distal tubuli in immunohistochem-
istry could be explained by renal filtration, but ISH
also show a positive signal for SLPI mRNA in tubuli.
These results imply local SLPI production in normal
kidney,  which  is  something  that  has  not  been
demonstrated before. Our primary antibody has been
used in many previous studies with clear-cut results,
and must be considered highly specific.12 For our ISH,
we used an oligonucleotide cocktail synthesised for
us by R&D Systems. These probes have worked well
in previous studies, and the negative results obtained
with  the  matched sense-strand probes  confirm  the
specificity  of  the  reaction  for  SLPI.12 The  known
function  of  SLPI  is  local  inhibition  of  activity  and
release of proteolytic enzymes.1,10 Considering this,
the role of SLPI in kidney would be to take part in a
local  regulation  of  proteolytic  activity  in  various
inflammatory conditions. SLPI might  also, consider-
ing  its  antimicrobial  and  antiviral  effects,1,2 be  of
importance in the defence against ascending urinary
tract infections. Of course, one could also anticipate
new  mechanisms  for  SLPI  action  in  this  context.
Hence, the conclusion of this paper is that we have
been able to demonstrate a novel local SLPI produc-
tion in kidney, the role of which needs to be further
elucidated.
ACKNOWLEDGEMENTS.  This  study  was  supported  by  grants  from  the
Swedish Medical Research Council (projects 3910, 71X-09487), the Founda-
tions  of Alfred  ¨ Osterlund  and Johan and  Greta  Koch,  the Foundation  for
Strategic Research and the Medical Faculty, Lund University. Dept of Urology
and  Dept  of  Pathology,  Lund  University  Hospital  for  providing  tissue
specimens.
References
1. Carmichael DF, Ohlsson K. Chemistry and biology of secretory leukopro-
tease  inhibitor.  In:  Crystal  RG,  ed.  Alpha-1-antitrypsin  Deficiency.
Biology.  Pathogenesis.  Clinical  Manifestations.  Therapy.  New York:
Mercel Dekker, 1996: 193–208.
2. Hiemstra  PS,  Maassen  RJ,  Stolk  J,  et  al. Antimicrobial  activity  of
antileucoprotease. Infect Immun 1996; 64: 4520–4524.
SLPI production in human kidney
Mediators of Inflammation · Vol 10 · 2001 349
FIG. 1. Immunohistochemical staining for SLPI on healthy
kidney biopsies, with goat anti-SLPI diluted 1/1000 and DAB
as a chromogen, showing positive signal in the tubuli. Scale
bar, 20mm.
FIG. 2. Demonstration of SLPI mRNA by in situ hybridisation
of healthy kidney biopsies. The specimens were hybridised
using an equimolar cocktail of three 30-base long antisense,
DIG-labelled oligonucleotides as probes. Positive staining is
seen in the tubuli. Scale bar, 80mm.3. Mc Neely TB, Shugars DC, RosendahlM, Tucker C, Eisenberg SP, Wahl SM.
Inhibition  of  human  immunodeficiency  virus  type  1  infectivity  by
secretory  leucocyte  protease  inhibitor  occurs  prior  to  viral  reverse
transcription. Blood 1997; 90: 1141–1149.
4. BruchM, Bieth JG. Influence of elastin on the inhibition of leucocyte
elastase by alpha-1-proteinase inhibitor and bronchial inhibitor: Potent
inhibition  of  elastin-bound  elastas by  bronchial  inhibitor.  Biochem  J
1986; 238: 269–273.
5. Sano C, Shimizu K, Sato H, et al. Effects of secretory leukocyte protease
inhibitor on the production of the anti-inflammatory cytokines, IL-10 and
transforming growth factor-beta (TGF-b). Clin Exp Immunol 2000; 121:
77–85.
6. MaruyamaM, Hay JG, Yoshimura K, Chu CS, Crystal RG. Modulation of
secretory leukoprotease inhibitor gene expression in human bronchial
epithelial cells by phorbol esters. J Clin Invest 1994; 94: 368–375.
7. Nystr¨ omM,  BergenfeldtM,  Ljungkrantz  I,  Lindeheim  Å,  Ohlsson  K.
Production  of secretory leucocyte protease inhibitor (SLPI) in human
pancreatic b-cells. Mediat Inflamm 1999; 8: 147–151.
8. Elzouki AN, SegelmarkM, Wieslander J, Eriksson S. Strong link between
the alpha-1-AT PiZ allele and WG. J Intern Med 1994; 236: 543–548.
9. BergenfeldtM, Axelsson L, Ohlsson K. Release of neutrophil proteinase 4
(3) and leukocyte elastase during phagocytosis and their interaction with
proteinase inhibitors. Scand J Clin Lab Invest 1992; 52: 823–829.
10. Zhang Y, De Witt DL, McNeely TB, Wahl SM, Wahl LM. Secretory leukocyte
protease inhibitor suppresses the production of monocyte prostaglandin
H  synthase-2, prostaglandin  E2 and  matrix metalloproteinases. J Clin
Invest 1997; 99: 894–900.
11. Daniel C, Duffield J, Brunner T, Steinmann-Niggli K, Lods N, Marti H-P.
Matrix metalloproteinase inhibitors cause cell cycle arrest and apoptosis
in  glomerular  mesangial  cells.  J  Pharmacol  Exp  Ther 2001;  297:
57–68.
12. Ohlsson  S,  Tufvesson  B,  Pålling  Å,  Ohlsson  K.  Distribution  of  the
secretory leucocyte proteinase  inhibitor  in human articular  cartilage.
Biol Chem 1997; 378: 1055–1058.
Received 12 August 2001
Accepted 6 September 2001
S. Ohlsson et al.
350 Mediators of Inflammation · Vol 10 · 2001